PROSTATE CANCER ADVISOR

Prostate Cancer

Features

AI Could Improve Prostate Cancer Brachytherapy

Enhanced deep-learning models have the potential to streamline prostate cancer brachytherapy treatment planning, according to investigators.
Imaging Needed to Identify Bone Metastases in Advanced PCa

Bone imaging cannot be safely omitted in advanced prostate cancer cases because no PSA level combined with T stage and Gleason Grade Group can accurately rule in bone metastases, a new study found.
Optimal mCRPC Drug Sequences Emerging

Recent studies provide guidance on which drugs should be used first to obtain the best outcomes.
Kegel Exercises After Prostate Surgery Called Into Question

Pelvic physical therapy may be more appropriate than Kegel exercises in managing post-radical prostatectomy pain and stress urinary incontinence, according to a new study.
Novel Antiandrogens and Cognitive Function

The authors of a recent review say they believe only a fraction of the men on androgen receptor-directed therapies who experience cognitive impairment report it.
Study Identifies Racial Differences in Prostate Cancer Gene Expression Tests

Commercially available gene expression tests for predicting prostate cancer progression appear to be less accurate in black vs white men, according to a new study.
Multidisciplinary Prostate Cancer Clinics May Promote Optimal Care

Receiving prostate cancer care at multidisciplinary clinics facilitates adherence to evidence-based national guidelines and potentially ameliorates bias in treatments, a study found.

Latest Prostate Cancer News

Human papillomavirus type 16 DNA in oral rinses is common at diagnosis, but rare after treatment for

HSD3B1 Genotype Tied to Worse Outcomes in Low-Volume mCSPC

May 25, 2020

New findings suggest that the HSD3B1 genotype can be used to risk stratify white men with low-volume metastatic prostate cancer.

A patient discusses a new oral medication regimen.

Local-Stage Prostate Cancer Incidence Rates Continue to Drop

May 22, 2020

Rates of regional- and distant-stage prostate cancer increasing in the US among men older than 50 years.

Olaparib Approved for Metastatic Castration-Resistant Prostate Cancer

Brian Park, PharmD

May 21, 2020

The FDA has approved Lynparza® (olaparib; AstraZeneca and Merck) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.

$ADT for more than 1 year is associated with a 2.5 times higher odds of fracture in prostate cancer p$

ADT May Decrease Risk of COVID-19 in Men With Prostate Cancer, Study Finds

Susan Moench, PhD, PA-C

May 21, 2020

TMPRSS2, a serine protease expressed in prostate and lung tissue that is necessary for SARS-CoV-2 viral infectivity of host cells, is activated by the androgen receptor.

PARP Inhibitor Approved for BRCA-Mutated mCRPC

Jody A. Charnow

May 19, 2020

FDA has approved rucaparib for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer in men previously treated with androgen-receptor directed therapy and taxane-based chemotherapy.

A trial in phase 2 metastatic prostate cancer shows that some patients likely to benefit from ipilimumab treatment, even with low number of tumor mutations.

Ipilimumab May Help Some Patients With Prostate Cancer—Even Those With Low TMB

Victoria Forster, PhD

May 6, 2020

A trial in phase 2 metastatic prostate cancer shows that some patients likely to benefit from ipilimumab treatment, even with low number of tumor mutations.

Study: Prostate Tumors Missed by mpMRI Less Aggressive

Jody A. Charnow

May 8, 2020

Post hoc analysis of the PROMIS cohort shows that tumors undetected by mpMRI are smaller and of lower grade than those that are detected.

Tissue biopsies to diagnose prostate cancer are invasive and they often miss cancer cells, which limits their utility for diagnosis.

Urine Biopsy Detects Biomarkers, Drug Targets in Prostate Cancer

Luisa Torres, PhD

April 23, 2020

Tissue biopsies to diagnose prostate cancer are invasive and they often miss cancer cells, which limits their utility for diagnosis.

Study: Earlier Use of Radium-223 May Offer Survival Edge

John Schieszer

May 7, 2020

Men with metastatic castration-resistant prostate cancer and symptomatic bone metastases had longer survival times when they received radium-223 as first-line therapy compared with those who received the drug as third-line therapy.